CIRM Alpha Stem Clinic at UC San Diego Health
Select a study to learn more:
Spinal Cord Injury
Researchers at UC San Diego Health are collaborating with Neuralstem, Inc. to conduct a safety trial of a human spinal cord-derived neural stem cell line in people with paralysis due to a spinal cord injury.
This clinical trial evaluates the safety of transplanting neural stem cells into the spine.
To learn about eligibility for this clinical trial, please call the Alpha Stem Cell Clinic (844) 317-STEM (7836) or e-mail
alphastemcellclinic@ucsd.edu.
Chronic Lymphocytic Leukemia
Researchers at UC San Diego Health are collaborating with Oncternal Therapeutics, Inc. to evaluate the effectiveness of the ROR1-targeting monoclonal antibody, cirmtuzumab, when given in combination with a BTK inhibitor, ibrutinib, in people with chronic lymphocytic leukemia, small lymphocytic leukemia or mantle cell lymphoma.
To learn about eligibility for this clinical trial, please contact Reilly Kidwell at 858-534-4801 or
rkidwell@ucsd.edu.
Type 1 Diabetes
Researchers at UC San Diego Health are collaborating with ViaCyte, Inc. to conduct a Phase I/II clinical trial of a combination product to treat people with type 1 diabetes and hypoglycemia unawareness.
The therapy involves implanting a device containing cells under the skin. This clinical trial evaluates the safety, tolerability and effectiveness of the combination product.
To learn about eligibility for this clinical trial, please call the CIRM Alpha Stem Cell Clinic (844) 317-STEM (7836) or e-mail
alphastemcellclinic@ucsd.edu.
Chronic Heart Failure
Researchers at UC San Diego Health are collaborating with Mesoblast, Ltd. to conduct a Phase III clinical trial of bone marrow-derived mesenchymal precursor cell (MPC) transplantation in people with chronic heart failure due to LV systolic dysfunction.
This study evaluates the effectiveness of transplanting bone marrow-derived allogeneic MPCs to treat chronic heart failure.
To learn about eligibility for this clinical trial, contact Aimee Barrera at 919-602-5311 or email Aimee.barrera@inventivhealth.com.
Myelodysplastic Syndromes
Researchers at UC San Diego Health are collaborating with Mesoblast, Ltd. to conduct a Phase III clinical trial of bone marrow-derived mesenchymal precursor cell (MPC) transplantation in people with chronic heart failure due to LV systolic dysfunction.
This study evaluates the effectiveness of transplanting bone marrow-derived allogeneic MPCs to treat chronic heart failure.
Degenerative Disc Disease
Researchers at UC San Diego Health are collaborating with DiscGenics, Inc. to conduct a Phase I/II clinical trial of an allogeneic cell therapy, administered via injection, in people with chronic low back pain due to degenerative disc disease at a single lumbar level.
To learn about eligibility for this clinical trial, please contact the UC San Diego Health CIRM Alpha Stem Cell Clinic at 844-317-STEM (7836) or
alphastemcellclinic@ucsd.edu.
Breast Cancer
Researchers at UC San Diego Health are collaborating with Oncternal Therapeutics, Inc. to evaluate the effectiveness of the ROR-1 targeting monoclonal antibody, cirmtuzumab, when given in combination with paclitaxel in people with HER2 negative, metastatic breast cancer.
Cirmtuzumab is an investigational drug that is designed to attach to a protein called ROR-1 and block the growth and survival of breast cancer cells.
To learn about eligibility for this clinical trial, please contact Jillian McCarthy, MPH, at 858-822-4516 or email
jmccarthy@ucsd.edu.